Why Are Karyopharm Therapeutics Shares Gaining Today?
Portfolio Pulse from Vandana Singh
Karyopharm Therapeutics Inc's shares are trading higher after the FDA granted Fast Track Designation to the development program of selinexor for myelofibrosis. The company initiated a pivotal Phase 3 trial in June 2023 and plans to expand its clinical development program in myelofibrosis. Top-line data from the Phase 3 study is expected in 2025. KPTI shares are up 20.90% at $1.85 during the premarket session.
July 18, 2023 | 1:12 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Karyopharm Therapeutics' stock is trading higher after the FDA granted Fast Track Designation to selinexor for myelofibrosis. This positive regulatory development and the ongoing Phase 3 trial could potentially boost the company's stock in the short term.
The FDA's Fast Track Designation is a positive regulatory development for Karyopharm Therapeutics, indicating that the agency recognizes the potential of selinexor for treating myelofibrosis. This, coupled with the ongoing Phase 3 trial, could potentially boost investor confidence and drive the company's stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100